# Lyfegen HealthTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lyfegen-healthtech

- Industry: Healthcare IT
- Headquarters: Basel, Switzerland
- Website: www.lyfegen.com/
- Total disclosed funding: $14M
- Latest round: Series A (Dec 11, 2024)
- Investors on record: 3

## About

Based in Switzerland, Lyfegen offers innovative digital solutions to improve access to pharmaceuticals and enhance healthcare system efficiency through its specialized platform.Founded in 2018 and headquartered in Basel, Switzerland, Lyfegen HealthTech AG is focused on connecting pharmaceutical companies with healthcare payers and providers. The company was co-founded by Girisha Fernando and Michel Mohler. In December 2024, Lyfegen raised 5.000 mn CHF in a Series A funding round led by TX Ventures, with participation from aMoon, bringing the total amount raised to 5.000 mn CHF. The company has engaged in 5 significant deals since its inception.Lyfegen specializes in providing innovative digital solutions designed to streamline access to pharmaceuticals and enhance efficiency within healthcare systems. Their core offerings include a platform that connects pharmaceutical companies with payers and providers, facilitating greater transparency and accessibility in medication distribution. This platform aims to address critical challenges in the healthcare supply chain, such as reducing time-to-access for patients and improving medication adherence. Lyfegen's services are targeted primarily at healthcare stakeholders, including insurers, pharmacies, and hospitals, particularly in markets across North America and Europe. Through these solutions, the company serves a diverse client base that prioritizes enhancing patient care and optimizing pharmaceutical management.Lyfegen’s revenue model is structured around partnerships and subscription services, aimed at organizations seeking to improve their pharmaceutical procurement processes. Clients typically engage with the platform through subscription agreements, allowing them to access a suite of tools and features designed to improve medication accessibility and adherence. Transactions occur directly between Lyfegen and its clients, often involving an upfront subscription fee along with tiered pricing based on the level of service or volume of transactions managed through the platform. Specific pricing plans are tailored to the needs of healthcare providers and payers, ensuring that Lyfegen’s solutions deliver value while supporting the financial sustainability of their clients. The company’s flagship product is integral to its revenue generation, enabling the scalability of its services within the healthcare ecosystem.In December 2024, Lyfegen plans to utilize the recently raised funding of 5.000 mn CHF to accelerate its global expansion and extend the reach of its drug rebate management platform beyond Europe into new markets worldwide. The company is focusing on enhancing its product offerings and exploring new geographic regions to ensure broader market penetration.

## Funding rounds

- Series A, Dec 11, 2024, $5.7M — aMoon, TX Ventures
- Series A, Sep 20, 2022, $8M — Apex Ventures, aMoon

## Investors

- Apex Ventures (https://capitalatlas.ai/funds/apex-ventures) — Series A
- aMoon (https://capitalatlas.ai/funds/amoon) — Series A
- TX Ventures (https://capitalatlas.ai/funds/tx-ventures) — Series A